NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...
Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies. Uniting ALS Biotech, ...
Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...
Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical ...
CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from ...
QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS First clinical ...
Funding aims to bring high quality ALS care closer to home and more accessible for people living with ALS nationwide "Thanks to this transformational gift, we are able to support clinical programs ...
WASHINGTON — A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine recommends actions Congress, federal agencies, insurers, and others should take to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results